Cancer stem cells as a possible cause of castration-resistant prostate cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, the study of cancer stem cells and their role in the development of resistance to antitumor therapy, the progression and recurrence of malignant neoplasms has become an important topic of research. Many experimental studies have shown that cancer stem cells may be responsible for the initiation and progression of prostate cancer. The development of castration-resistant prostate cancer is accompanied by changes in the activity of many signaling pathways, such as WNT/β-catenin, interleukin 6 /STAT3, ALDH1, Notch1 and Hedgehog which regulate the genes responsible for pluripotency, self-renewal, and differentiation, indicating the presence of stem-like cells in the tumor.

 

 

About the authors

Rustam I. Shayakhmetov

Bashkir State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: sheikhakhmetov@yandex.ru
ORCID iD: 0009-0003-7673-1766

Institute of Urology and Clinical Oncology

 

Russian Federation, 3 Leninа St., Ufa 450008

T. Ch. Le

Bashkir State Medical University, Ministry of Health of Russia

Email: sheikhakhmetov@yandex.ru
ORCID iD: 0009-0007-7467-5034

Institute of Urology and Clinical Oncology

 

Russian Federation, 3 Leninа St., Ufa 450008

D. V. Ishmetova

Bashkir State Medical University, Ministry of Health of Russia

Email: sheikhakhmetov@yandex.ru
ORCID iD: 0000-0001-9393-2875

Institute of Urology and Clinical Oncology

 

Russian Federation, 3 Leninа St., Ufa 450008

A. I. Rakhmatullina

Bashkir State Medical University, Ministry of Health of Russia

Email: sheikhakhmetov@yandex.ru
ORCID iD: 0009-0009-8191-9951

Institute of Urology and Clinical Oncology

 

Russian Federation, 3 Leninа St., Ufa 450008

R. R. Ishmugulov

Bashkir State Medical University, Ministry of Health of Russia

Email: prorectornir@bashgmu.ru

Institute of Urology and Clinical Oncology

 

Russian Federation, 3 Leninа St., Ufa 450008

V. N. Pavlov

Bashkir State Medical University, Ministry of Health of Russia

Email: sheikhakhmetov@yandex.ru
ORCID iD: 0000-0003-2125-4897

Institute of Urology and Clinical Oncology

 

Russian Federation, 3 Leninа St., Ufa 450008

References

  1. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).
  2. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. doi: 10.3322/caac.21834
  3. Yu C., Yao Z., Jiang Y., Keller E.T. Prostate cancer stem cell biology. Minerva Urol Nefrol 2012;64(1):19–33.
  4. Omelchuk E.P., Kutilin D.S., Dimitriadis S.N. et al. Molecular and genetic aspects of prostate cancer radioresistance. Bulletin of Siberian Medicine 2021;20(3):182–92. (In Russ.).
  5. Virchow R. Editoral Archiv fuer pathologische Anatomie und Physiologie und fuer klinische Medizin. Berlin, 1855. (In German). Available at: https://books.google.ru/books/about/Archiv_f%C3%BCr_pathologische_Anatomie_und_P.html?id=6IYvAAAAIAAJ&redir_esc=y
  6. Cohnheim J. Ueber entzundung und eiterung. Path Anat Physiol Klin Med 1867;40:1–79. Available at: https://link.springer.com/article/10.1007/BF02968135
  7. Bruce W.R., van der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963;199:79–80. doi: 10.1038/199079a0
  8. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3(7):730–7. doi: 10.1038/nm0797-730
  9. Al-Hajj M., Wicha M.S., Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983–8. doi: 10.1073/pnas.0530291100
  10. Kim C.F., Jackson E.L., Woolfenden A.E. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823–35. doi: 10.1016/j.cell.2005.03.032
  11. O’Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445(7123):106–10. doi: 10.1038/nature05372
  12. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T. et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006;103(30):11154–9. doi: 10.1073/pnas.0603672103
  13. Piccirillo S.G.M., Reynolds B.A., Zanetti N. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444(7120):761–5. doi: 10.1038/nature05349
  14. Collins A.T., Berry P.A., Hyde C. et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946–51. doi: 10.1158/0008-5472.CAN-05-2018
  15. Miller S.J., Lavker R.M., Sun T.T. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 2005;1756(1):25–52. doi: 10.1016/j.bbcan.2005.07.003
  16. Vezzoni L., Parmiani G. Limitations of the cancer stem cell theory. Cytotechnology 2008;58:3–9. doi: 10.1007/s10616-008-9166-8
  17. Fabian A., Vereb G., Szollosi J. The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy. Cytometry A 2013; 83(1):62–71. doi: 10.1002/cyto.a.22206
  18. Ni C., Huang J. Dynamic regulation of cancer stem cells and clinical challenges. Clin Transl Oncol 2013;15(4):253–8. doi: 10.1007/s12094-012-0927-7
  19. Saunders N.A., Simpson F., Thompson E.W. et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 2012;4(8):675–84. doi: 10.1002/emmm.201101131
  20. Di Lorenzo G., Autorino R., D’Armiento F.P. et al. Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 2004;30(9):987–92. doi: 10.1016/j.ejso.2004.07.017
  21. Patrawala L., Calhoun-Davis T., Schneider-Broussard R. et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67(14):6796–805. doi: 10.1158/0008-5472.CAN-07-0490
  22. Burger P.E., Gupta R., Xiong X. et al. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009;27(9):2220–8. doi: 10.1002/stem.135
  23. Ugolkov A.V., Eisengart L.J., Luan C. et al. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2011;71(1):18–25. doi: 10.1002/pros.21217
  24. Trerotola M., Li J., Alberti S. et al. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol 2012;227(11):3670–7. doi: 10.1002/jcp.24074
  25. Fang Y., Fliss A.E., Robins D.M. et al. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996;271(45):28697–702. doi: 10.1074/jbc.271.45.28697
  26. Askew E.B., Gampe R.T. Jr., Stanley T.B. et al. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007;282(35):25801–16. doi: 10.1074/jbc.M703268200
  27. Balk S., Knudsen K. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008;6:e001. doi: 10.1621/nrs.06001
  28. Penning T.M. Dehydroepiandrosterone (DHEA)-SO4 depot and castration-resistant prostate cancer. Vitam Horm 2018;108:309–31. doi: 10.1016/bs.vh.2018.01.007
  29. Nyquist M.D., Corella A., Coleman I. et al. Combined TP53 and RB1 Loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep 2020;31(8):107669. doi: 10.1016/j.celrep.2020.107669
  30. Van der Steen T., Tindall D.J., Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci 2013;14(7):14833–59. doi: 10.3390/ijms140714833
  31. Le T.K., Duong Q.H., Baylot V. et al. Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers (Basel) 2023;15(20):5047. doi: 10.3390/cancers15205047
  32. Fu X., Liu J., Yan X. et al. Heat shock protein 70 and 90 family in prostate cancer. Life (Basel) 2022;12(10):1489. doi: 10.3390/life12101489
  33. Truica C.I., Byers S., Gelmann E.P. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60(17):4709–13.
  34. Wan X., Liu J., Lu J.F. et al. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 2012;18(3):726–36. doi: 10.1158/1078-0432.CCR-11-2521
  35. Rajan P., Sudbery I.M., Villasevil M.E. et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol 2014 ;66(1):32–9. doi: 10.1016/j.eururo.2013.08.011
  36. Koushyar S., Meniel V.S., Phesse T.J. et al. Exploring the Wnt pathway as a therapeutic target for prostate cancer. Biomolecules 2022;12(2):309. doi: 10.3390/biom12020309
  37. Chesire D.R., Ewing C.M., Gage W.R. et al. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002;21(12):2679–94. doi: 10.1038/sj.onc.1205352
  38. Lee G.T., Kwon S.J., Kim J. et al. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer 2018;118(5):670–8. doi: 10.1038/bjc.2017.451
  39. Bisson I., Prowse D.M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009;19:683–97. doi: 10.1038/cr.2009.43
  40. Huang B., Lang X., Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol 2022;12:1023177. doi: 10.3389/fonc.2022.1023177
  41. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9(11):798–809. doi: 10.1038/nrc2734
  42. Bronte-Tinkew D.M., Terebiznik M., Franco A. et al. Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res 2009;69(2):632–9. doi: 10.1158/0008-5472.CAN-08-1191
  43. Wu S., Rhee K.J., Albesiano E. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Med 2009;15(9):1016–22. doi: 10.1038/nm.2015
  44. Samavati L., Rastogi R., Du W. et al. STAT3 tyrosine phosphorylation is critical for interleukin 1β and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol 2009;46(8–9): 1867–77. doi: 10.1016/j.molimm.2009.02.018
  45. Darnell J.E. Jr., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264(5164):1415–21. doi: 10.1126/science.8197455
  46. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295–307. doi: 10.1038/nri1806
  47. Wu X., Tao P., Zhou Q. et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 2017;8(13):20741–50. doi: 10.18632/oncotarget.15119
  48. Banerjee K., Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer 2016;138(11):2570–8. doi: 10.1002/ijc.29923
  49. Singh A.K., Bhadauria A.S., Kumar U. et al. Novel fused oxazepino-indoles (FOIs) attenuate liver carcinogenesis via IL-6/JAK2/STAT3 signaling blockade as evidenced through data-based mathematical modeling. Life Sci 2018;201:161–72. doi: 10.1016/j.lfs.2018.02.029
  50. Zhang X., Hu F., Li G. et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis 2018;9(2):25. doi: 10.1038/s41419-017-0176-3
  51. Fang X., Hong Y., Dai L. et al. CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. Mol Carcinogene 2017;56(11):2434–45. doi: 10.1002/mc.22691
  52. Wang L., Zhang F., Cui J.Y. et al. CAFs enhance paclitaxel resistance by inducing EMT through the IL-6/JAK2/STAT3 pathway. Oncol Rep 2018;39(5):2081–90. doi: 10.3892/or.2018.6311
  53. Sun C., Yang J., Cheng H.B. et al. 2-Hydroxy-3-methylanthraquinone inhibits lung carcinoma cells through modulation of IL-6-induced JAK2/STAT3 pathway. Phytomedicine 2019;61:152848. doi: 10.1016/j.phymed.2019.152848
  54. Zhang X., Lu H., Hong W. et al. Tyrphostin B42 attenuates trichostatin a-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. Oncol Rep 2018;39(4):1892–900. doi: 10.3892/or.2018.6241
  55. Culig Z., Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012;360(1–2):52–8. doi: 10.1016/j.mce.2011.05.033
  56. Adler H.L., McCurdy M.A., Kattan M.W. et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161(1):182–7.
  57. Schroeder A., Herrmann A., Cherryholmes G. et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res 2014;74(4):1227–37. doi: 10.1158/0008-5472.CAN-13-0594
  58. Schnier J.B., Kaur G., Kaiser A. et al. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett 1999;454(1–2):100–4. doi: 10.1016/s0014-5793(99)00773-5
  59. Li T., Su Y., Mei Y. et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Invest 2010;90(2):234–44. doi: 10.1038/labinvest.2009.127
  60. Kalantari E., Saadi F.H., Asgari M. et al. Increased expression of ALDH1A1 in prostate cancer is correlated with tumor aggressiveness: a tissue microarray study of iranian patients. Appl Immunohistochem Mol Morphol 2017;25(8):592–8. doi: 10.1097/PAI.0000000000000343
  61. Matsika A., Srinivasan B., Day C. et al. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. Pathology 2015;47(7):622–8. doi: 10.1097/PAT.0000000000000325
  62. Van den Hoogen C., van der Horst G., Cheung H. et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010;70(12):5163–73. doi: 10.1158/0008-5472.CAN-09-3806
  63. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24(18):1967–2000. doi: 10.1101/gad.1965810
  64. Zhu H., Zhou X., Redfield S. et al. Elevated EXpression of Notch1 Is associated with metastasis of human malignancies. Int J Surg Pathol 2013;21(5):449–54. doi: 10.1177/1066896913496146
  65. Stoyanova T., Riedinger M., Lin S. et al. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci USA 2016;113(42):E6457–66. doi: 10.1073/pnas.1614529113
  66. Wu K., Wu M., Yang H. et al. Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1α/Notch1 signaling pathway. Clin Transl Oncol 2023;25(7):2138–52. doi: 10.1007/s12094-023-03093-w
  67. Shi F., Sun M.H., Zhou Z. et al. Tumor-associated macrophages in direct contact with prostate cancer cells promote malignant proliferation and metastasis through NOTCH1 pathway. Int J Biol Sci 2022;18(16):5994–6007. doi: 10.7150/ijbs.73141
  68. Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol 2022;85:107–22. doi: 10.1016/j.semcancer.2021.04.003
  69. Cohen M.M. Jr. The hedgehog signaling network. Am J Med Genet A 2003;123A(1):5–28. doi: 10.1002/ajmg.a.20495
  70. Lv L., Yang Z., Ma T. et al. Gli1, a potential cancer stem cell marker, is strongly associated with prognosis in prostate cancer. Int J Clin Exp Pathol 2018;11(10):4957–66.
  71. Kim T.J., Lee J.Y., Hwang T.K. et al. Hedgehog signaling protein expression and its association with prognostic parameters in prostate cancer: a retrospective study from the view point of new 2010 anatomic stage/prognostic groups. J Surg Oncol 2011;104(5):472–9. doi: 10.1002/jso.21988
  72. Bernard D., Pourtier-Manzanedo A., Gil J. et al. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003;112(11):1724–31. doi: 10.1172/JCI19035
  73. Klarmann G.J., Hurt E.M., Mathews L.A. et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009;26(5):433–46. doi: 10.1007/s10585-009-9242-2
  74. Atawia I.M., Kushwaha P.P., Verma S. et al. Inhibition of Wnt/β-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. Mol Carcinog 2023;62(9):1312–24. doi: 10.1002/mc.23565
  75. Liu Y.M., Wu A.D., Chen Y. et al. Gastrodin inhibits prostate cancer proliferation by targeting canonical Wnt/β-catenin signaling pathway. Med Oncol 2023;41(1):32. doi: 10.1007/s12032-023-02254-9
  76. Saito S., Ando K., Sakamoto S. et al. The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism. Cancer Sci 2024;115(7):2461–72. doi: 10.1111/cas.16191
  77. Lee M.H., Kundu J.K., Keum Y.S. et al. Resveratrol Inhibits IL-6-induced transcriptional activity of AR and STAT3 in human prostate cancer LNCaP-FGC cells. Biomol Ther (Seoul) 2014;22(5):426–30. doi: 10.4062/biomolther.2014.061
  78. Cao H., Feng Y., Sun P. et al. Zhoushi Qiling decoction inhibits proliferation of human prostate cancer cells through IL6/STAT3 pathway. J Cancer 2023;14(12):2246–54. doi: 10.7150/jca.84943
  79. Cai F., Guo S., Huang S. et al. Rubimaillin suppresses proliferation, migration and invasion of prostate cancer cells via the Notch-1/MMP signaling pathway. Cell Mol Biol (Noisy-le-grand) 2020;66(2):130–4.
  80. Cai M., Ge S., Hong Y. et al. Tegaserod maleate exerts anti-tumor effects on prostate cancer via repressing sonic hedgehog signaling pathway. Mol Med 2025;31(1):30. doi: 10.1186/s10020-025-01080-1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-57560 от  08.04.2014.